#immunogenicity — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #immunogenicity, aggregated by home.social.
-
#Safety and #immunogenicity of ascending doses of #influenza A(#H7N9) inactivated #vaccine with or without MF59®, https://etidiohnew.blogspot.com/2025/01/safety-and-immunogenicity-of-ascending.html
-
#Safety and #immunogenicity of ascending doses of #influenza A(#H7N9) inactivated #vaccine with or without MF59®, https://etidiohnew.blogspot.com/2025/01/safety-and-immunogenicity-of-ascending.html
-
#Safety and #immunogenicity of ascending doses of #influenza A(#H7N9) inactivated #vaccine with or without MF59®, https://etidiohnew.blogspot.com/2025/01/safety-and-immunogenicity-of-ascending.html
-
#Safety and #immunogenicity of ascending doses of #influenza A(#H7N9) inactivated #vaccine with or without MF59®, https://etidiohnew.blogspot.com/2025/01/safety-and-immunogenicity-of-ascending.html
-
#Safety and #immunogenicity of ascending doses of #influenza A(#H7N9) inactivated #vaccine with or without MF59®, https://etidiohnew.blogspot.com/2025/01/safety-and-immunogenicity-of-ascending.html
-
#Immunogenicity of a #booster dose of a bivalent (Asp614Gly and #omicron BA.4/5 #variant) self-amplifying #mRNA #SARS-CoV-2 booster vaccine versus the BNT162b2 omicron BA.4/5 mRNA vaccine: a randomised phase 3 trial
Source: Lancet Infectious Diseases, SummaryBackgroundWe previously showed that ARCT-154, a self-amplifying mRNA COVID-19 vaccine, had improved immunogenicity and antibody persistence compared with conventional mRNA or adenovirus vector vaccines. In this…
-
#Immunogenicity of a #booster dose of a bivalent (Asp614Gly and #omicron BA.4/5 #variant) self-amplifying #mRNA #SARS-CoV-2 booster vaccine versus the BNT162b2 omicron BA.4/5 mRNA vaccine: a randomised phase 3 trial
Source: Lancet Infectious Diseases, SummaryBackgroundWe previously showed that ARCT-154, a self-amplifying mRNA COVID-19 vaccine, had improved immunogenicity and antibody persistence compared with conventional mRNA or adenovirus vector vaccines. In this…
-
#Immunogenicity of a #booster dose of a bivalent (Asp614Gly and #omicron BA.4/5 #variant) self-amplifying #mRNA #SARS-CoV-2 booster vaccine versus the BNT162b2 omicron BA.4/5 mRNA vaccine: a randomised phase 3 trial
Source: Lancet Infectious Diseases, SummaryBackgroundWe previously showed that ARCT-154, a self-amplifying mRNA COVID-19 vaccine, had improved immunogenicity and antibody persistence compared with conventional mRNA or adenovirus vector vaccines. In this…
-
#Immunogenicity of a #booster dose of a bivalent (Asp614Gly and #omicron BA.4/5 #variant) self-amplifying #mRNA #SARS-CoV-2 booster vaccine versus the BNT162b2 omicron BA.4/5 mRNA vaccine: a randomised phase 3 trial
Source: Lancet Infectious Diseases, SummaryBackgroundWe previously showed that ARCT-154, a self-amplifying mRNA COVID-19 vaccine, had improved immunogenicity and antibody persistence compared with conventional mRNA or adenovirus vector vaccines. In this…
-
#Immunogenicity of a #booster dose of a bivalent (Asp614Gly and #omicron BA.4/5 #variant) self-amplifying #mRNA #SARS-CoV-2 booster vaccine versus the BNT162b2 omicron BA.4/5 mRNA vaccine: a randomised phase 3 trial
Source: Lancet Infectious Diseases, SummaryBackgroundWe previously showed that ARCT-154, a self-amplifying mRNA COVID-19 vaccine, had improved immunogenicity and antibody persistence compared with conventional mRNA or adenovirus vector vaccines. In this…
-
#Safety, #immunogenicity, and optimal dosing of a MVA-based #vaccine against #MERS-CoV in healthy adults: a phase 1b, double-blind, randomised placebo-controlled clinical trial
Source: Lancet Infectious Diseases, SummaryBackgroundMERS-CoV is a respiratory pathogen with a case-fatality rate of 36%, and for which no vaccines are currently licensed. MVA-MERS-S is a candidate vaccine based on recombinant modified vaccinia virus Ankara (MVA). In this study, the safety,…
-
#Safety, #immunogenicity, and optimal dosing of a MVA-based #vaccine against #MERS-CoV in healthy adults: a phase 1b, double-blind, randomised placebo-controlled clinical trial
Source: Lancet Infectious Diseases, SummaryBackgroundMERS-CoV is a respiratory pathogen with a case-fatality rate of 36%, and for which no vaccines are currently licensed. MVA-MERS-S is a candidate vaccine based on recombinant modified vaccinia virus Ankara (MVA). In this study, the safety,…
-
#Safety, #immunogenicity, and optimal dosing of a MVA-based #vaccine against #MERS-CoV in healthy adults: a phase 1b, double-blind, randomised placebo-controlled clinical trial
Source: Lancet Infectious Diseases, SummaryBackgroundMERS-CoV is a respiratory pathogen with a case-fatality rate of 36%, and for which no vaccines are currently licensed. MVA-MERS-S is a candidate vaccine based on recombinant modified vaccinia virus Ankara (MVA). In this study, the safety,…
-
#Safety, #immunogenicity, and optimal dosing of a MVA-based #vaccine against #MERS-CoV in healthy adults: a phase 1b, double-blind, randomised placebo-controlled clinical trial
Source: Lancet Infectious Diseases, SummaryBackgroundMERS-CoV is a respiratory pathogen with a case-fatality rate of 36%, and for which no vaccines are currently licensed. MVA-MERS-S is a candidate vaccine based on recombinant modified vaccinia virus Ankara (MVA). In this study, the safety,…
-
#Safety, #immunogenicity, and optimal dosing of a MVA-based #vaccine against #MERS-CoV in healthy adults: a phase 1b, double-blind, randomised placebo-controlled clinical trial
Source: Lancet Infectious Diseases, SummaryBackgroundMERS-CoV is a respiratory pathogen with a case-fatality rate of 36%, and for which no vaccines are currently licensed. MVA-MERS-S is a candidate vaccine based on recombinant modified vaccinia virus Ankara (MVA). In this study, the safety,…
-
Preclinical #immunogenicity and #safety of #hemagglutinin-encoding #modRNA #influenza #vaccines
Source: npj Vaccines, AbstractSeasonal epidemics of influenza viruses are responsible for a significant global public health burden. Vaccination remains the most effective way to prevent infection; however, due to the persistence of antigenic drift, vaccines must be updated annually. The selection of vaccine strains occurs months in advance of the influenza season to allow…
-
Preclinical #immunogenicity and #safety of #hemagglutinin-encoding #modRNA #influenza #vaccines
Source: npj Vaccines, AbstractSeasonal epidemics of influenza viruses are responsible for a significant global public health burden. Vaccination remains the most effective way to prevent infection; however, due to the persistence of antigenic drift, vaccines must be updated annually. The selection of vaccine strains occurs months in advance of the influenza season to allow…
-
Preclinical #immunogenicity and #safety of #hemagglutinin-encoding #modRNA #influenza #vaccines
Source: npj Vaccines, AbstractSeasonal epidemics of influenza viruses are responsible for a significant global public health burden. Vaccination remains the most effective way to prevent infection; however, due to the persistence of antigenic drift, vaccines must be updated annually. The selection of vaccine strains occurs months in advance of the influenza season to allow…
-
Preclinical #immunogenicity and #safety of #hemagglutinin-encoding #modRNA #influenza #vaccines
Source: npj Vaccines, AbstractSeasonal epidemics of influenza viruses are responsible for a significant global public health burden. Vaccination remains the most effective way to prevent infection; however, due to the persistence of antigenic drift, vaccines must be updated annually. The selection of vaccine strains occurs months in advance of the influenza season to allow…
-
Preclinical #immunogenicity and #safety of #hemagglutinin-encoding #modRNA #influenza #vaccines
Source: npj Vaccines, AbstractSeasonal epidemics of influenza viruses are responsible for a significant global public health burden. Vaccination remains the most effective way to prevent infection; however, due to the persistence of antigenic drift, vaccines must be updated annually. The selection of vaccine strains occurs months in advance of the influenza season to allow…
-
#Safety and #immunogenicity of #mRNA-based seasonal #influenza #vaccines formulated to include multiple #H3N2 strains with or without the B/Yamagata strain in #US adults aged 50–75 years: a phase 1/2, open-label, randomised trial, Lancet Infect Dis.: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00493-6/abstract?rss=yes
These data support the continued clinical development of mRNA-based next-generation seasonal influenza vaccines with broadened influenza A/H3N2 strain coverage.
-
#Safety and #immunogenicity of #mRNA-based seasonal #influenza #vaccines formulated to include multiple #H3N2 strains with or without the B/Yamagata strain in #US adults aged 50–75 years: a phase 1/2, open-label, randomised trial, Lancet Infect Dis.: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00493-6/abstract?rss=yes
These data support the continued clinical development of mRNA-based next-generation seasonal influenza vaccines with broadened influenza A/H3N2 strain coverage.
-
#Safety and #immunogenicity of #mRNA-based seasonal #influenza #vaccines formulated to include multiple #H3N2 strains with or without the B/Yamagata strain in #US adults aged 50–75 years: a phase 1/2, open-label, randomised trial, Lancet Infect Dis.: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00493-6/abstract?rss=yes
These data support the continued clinical development of mRNA-based next-generation seasonal influenza vaccines with broadened influenza A/H3N2 strain coverage.
-
#Safety and #immunogenicity of #mRNA-based seasonal #influenza #vaccines formulated to include multiple #H3N2 strains with or without the B/Yamagata strain in #US adults aged 50–75 years: a phase 1/2, open-label, randomised trial, Lancet Infect Dis.: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00493-6/abstract?rss=yes
These data support the continued clinical development of mRNA-based next-generation seasonal influenza vaccines with broadened influenza A/H3N2 strain coverage.
-
#Safety and #immunogenicity of #mRNA-based seasonal #influenza #vaccines formulated to include multiple #H3N2 strains with or without the B/Yamagata strain in #US adults aged 50–75 years: a phase 1/2, open-label, randomised trial, Lancet Infect Dis.: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00493-6/abstract?rss=yes
These data support the continued clinical development of mRNA-based next-generation seasonal influenza vaccines with broadened influenza A/H3N2 strain coverage.
-
#Immunogenicity & #biodistribution of lipid #nanoparticle formulated self-amplifying #mRNA #vaccines against #H5 avian #influenza, npj Vaccines: https://www.nature.com/articles/s41541-024-00932-x
Cellular immune responses & #antigen-specific #IgA antibodies in #lungs were also observed. Comparison of sa-mRNA vaccines encoding secreted & membrane-anchored full-length HA revealed that anchoring of HA to the membrane significantly enhanced the antibody and cellular responses.
-
#Immunogenicity & #biodistribution of lipid #nanoparticle formulated self-amplifying #mRNA #vaccines against #H5 avian #influenza, npj Vaccines: https://www.nature.com/articles/s41541-024-00932-x
Cellular immune responses & #antigen-specific #IgA antibodies in #lungs were also observed. Comparison of sa-mRNA vaccines encoding secreted & membrane-anchored full-length HA revealed that anchoring of HA to the membrane significantly enhanced the antibody and cellular responses.
-
#Immunogenicity & #biodistribution of lipid #nanoparticle formulated self-amplifying #mRNA #vaccines against #H5 avian #influenza, npj Vaccines: https://www.nature.com/articles/s41541-024-00932-x
Cellular immune responses & #antigen-specific #IgA antibodies in #lungs were also observed. Comparison of sa-mRNA vaccines encoding secreted & membrane-anchored full-length HA revealed that anchoring of HA to the membrane significantly enhanced the antibody and cellular responses.
-
#Immunogenicity & #biodistribution of lipid #nanoparticle formulated self-amplifying #mRNA #vaccines against #H5 avian #influenza, npj Vaccines: https://www.nature.com/articles/s41541-024-00932-x
Cellular immune responses & #antigen-specific #IgA antibodies in #lungs were also observed. Comparison of sa-mRNA vaccines encoding secreted & membrane-anchored full-length HA revealed that anchoring of HA to the membrane significantly enhanced the antibody and cellular responses.
-
#Immunogenicity & #biodistribution of lipid #nanoparticle formulated self-amplifying #mRNA #vaccines against #H5 avian #influenza, npj Vaccines: https://www.nature.com/articles/s41541-024-00932-x
Cellular immune responses & #antigen-specific #IgA antibodies in #lungs were also observed. Comparison of sa-mRNA vaccines encoding secreted & membrane-anchored full-length HA revealed that anchoring of HA to the membrane significantly enhanced the antibody and cellular responses.
-
A synthetic #TLR4 agonist significantly increases #humoral immune #responses and the protective ability of an #MDCK-cell-derived inactivated #H7N9 #vaccine in #mice, Arch Virol.: https://link.springer.com/article/10.1007/s00705-024-06082-8
Antigenically divergent H7N9 viruses pose a potential threat to public #health, with the poor #immunogenicity of candidate H7N9 vaccines demonstrated in clinical trials underscoring the urgent need for more-effective H7N9 vaccines.
-
A synthetic #TLR4 agonist significantly increases #humoral immune #responses and the protective ability of an #MDCK-cell-derived inactivated #H7N9 #vaccine in #mice, Arch Virol.: https://link.springer.com/article/10.1007/s00705-024-06082-8
Antigenically divergent H7N9 viruses pose a potential threat to public #health, with the poor #immunogenicity of candidate H7N9 vaccines demonstrated in clinical trials underscoring the urgent need for more-effective H7N9 vaccines.
-
A synthetic #TLR4 agonist significantly increases #humoral immune #responses and the protective ability of an #MDCK-cell-derived inactivated #H7N9 #vaccine in #mice, Arch Virol.: https://link.springer.com/article/10.1007/s00705-024-06082-8
Antigenically divergent H7N9 viruses pose a potential threat to public #health, with the poor #immunogenicity of candidate H7N9 vaccines demonstrated in clinical trials underscoring the urgent need for more-effective H7N9 vaccines.
-
A synthetic #TLR4 agonist significantly increases #humoral immune #responses and the protective ability of an #MDCK-cell-derived inactivated #H7N9 #vaccine in #mice, Arch Virol.: https://link.springer.com/article/10.1007/s00705-024-06082-8
Antigenically divergent H7N9 viruses pose a potential threat to public #health, with the poor #immunogenicity of candidate H7N9 vaccines demonstrated in clinical trials underscoring the urgent need for more-effective H7N9 vaccines.
-
A synthetic #TLR4 agonist significantly increases #humoral immune #responses and the protective ability of an #MDCK-cell-derived inactivated #H7N9 #vaccine in #mice, Arch Virol.: https://link.springer.com/article/10.1007/s00705-024-06082-8
Antigenically divergent H7N9 viruses pose a potential threat to public #health, with the poor #immunogenicity of candidate H7N9 vaccines demonstrated in clinical trials underscoring the urgent need for more-effective H7N9 vaccines.
-
A Phase 2 Clinical Trial to Evaluate the #Safety, Reactogenicity, and #Immunogenicity of Different Prime-Boost #Vaccination Schedules of '13 & '17 #H7N9 Inactivated #Influenza Virus Vaccines Administered with & without #AS03 Adjuvant in Healthy US Adults, Clin Infect Dis.: https://doi.org/10.1093/cid/ciae173
Administering adjuvant with 2nd H7N9 IIV dose & extending boost interval to 4 mos resulted in higher peak Ab responses. These observations can inform strategic approaches for pandemic preparedness.
-
A Phase 2 Clinical Trial to Evaluate the #Safety, Reactogenicity, and #Immunogenicity of Different Prime-Boost #Vaccination Schedules of '13 & '17 #H7N9 Inactivated #Influenza Virus Vaccines Administered with & without #AS03 Adjuvant in Healthy US Adults, Clin Infect Dis.: https://doi.org/10.1093/cid/ciae173
Administering adjuvant with 2nd H7N9 IIV dose & extending boost interval to 4 mos resulted in higher peak Ab responses. These observations can inform strategic approaches for pandemic preparedness.
-
A Phase 2 Clinical Trial to Evaluate the #Safety, Reactogenicity, and #Immunogenicity of Different Prime-Boost #Vaccination Schedules of '13 & '17 #H7N9 Inactivated #Influenza Virus Vaccines Administered with & without #AS03 Adjuvant in Healthy US Adults, Clin Infect Dis.: https://doi.org/10.1093/cid/ciae173
Administering adjuvant with 2nd H7N9 IIV dose & extending boost interval to 4 mos resulted in higher peak Ab responses. These observations can inform strategic approaches for pandemic preparedness.
-
A Phase 2 Clinical Trial to Evaluate the #Safety, Reactogenicity, and #Immunogenicity of Different Prime-Boost #Vaccination Schedules of '13 & '17 #H7N9 Inactivated #Influenza Virus Vaccines Administered with & without #AS03 Adjuvant in Healthy US Adults, Clin Infect Dis.: https://doi.org/10.1093/cid/ciae173
Administering adjuvant with 2nd H7N9 IIV dose & extending boost interval to 4 mos resulted in higher peak Ab responses. These observations can inform strategic approaches for pandemic preparedness.
-
A Phase 2 Clinical Trial to Evaluate the #Safety, Reactogenicity, and #Immunogenicity of Different Prime-Boost #Vaccination Schedules of '13 & '17 #H7N9 Inactivated #Influenza Virus Vaccines Administered with & without #AS03 Adjuvant in Healthy US Adults, Clin Infect Dis.: https://doi.org/10.1093/cid/ciae173
Administering adjuvant with 2nd H7N9 IIV dose & extending boost interval to 4 mos resulted in higher peak Ab responses. These observations can inform strategic approaches for pandemic preparedness.
-
[Articles] #Immunogenicity and #safety of a #booster dose of a self-amplifying #RNA #COVID19 #vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00650-3/fulltext?rss=yes
-
[Articles] #Immunogenicity and #safety of a #booster dose of a self-amplifying #RNA #COVID19 #vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00650-3/fulltext?rss=yes
-
[Articles] #Immunogenicity and #safety of a #booster dose of a self-amplifying #RNA #COVID19 #vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00650-3/fulltext?rss=yes
-
[Articles] #Immunogenicity and #safety of a #booster dose of a self-amplifying #RNA #COVID19 #vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00650-3/fulltext?rss=yes
-
[Articles] #Immunogenicity and #safety of a #booster dose of a self-amplifying #RNA #COVID19 #vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00650-3/fulltext?rss=yes
-
#Immunogenicity and safety of varying dosages of a fifth-wave #influenza A/ #H7N9 inactivated #vaccine given with and without #AS03 adjuvant in healthy adults https://pubmed.ncbi.nlm.nih.gov/38105137/?utm_source=Feedly&utm_medium=rss&utm_campaign=None&utm_content=1LGAx__djGAJ9poBzWGqPtjEbBDtz4ipSRRPUplmgHEyyF_Ihj&fc=None&ff=20231218031744&v=2.18.0
-
#Immunogenicity and safety of varying dosages of a fifth-wave #influenza A/ #H7N9 inactivated #vaccine given with and without #AS03 adjuvant in healthy adults https://pubmed.ncbi.nlm.nih.gov/38105137/?utm_source=Feedly&utm_medium=rss&utm_campaign=None&utm_content=1LGAx__djGAJ9poBzWGqPtjEbBDtz4ipSRRPUplmgHEyyF_Ihj&fc=None&ff=20231218031744&v=2.18.0
-
#Immunogenicity and safety of varying dosages of a fifth-wave #influenza A/ #H7N9 inactivated #vaccine given with and without #AS03 adjuvant in healthy adults https://pubmed.ncbi.nlm.nih.gov/38105137/?utm_source=Feedly&utm_medium=rss&utm_campaign=None&utm_content=1LGAx__djGAJ9poBzWGqPtjEbBDtz4ipSRRPUplmgHEyyF_Ihj&fc=None&ff=20231218031744&v=2.18.0
-
#Immunogenicity and safety of varying dosages of a fifth-wave #influenza A/ #H7N9 inactivated #vaccine given with and without #AS03 adjuvant in healthy adults https://pubmed.ncbi.nlm.nih.gov/38105137/?utm_source=Feedly&utm_medium=rss&utm_campaign=None&utm_content=1LGAx__djGAJ9poBzWGqPtjEbBDtz4ipSRRPUplmgHEyyF_Ihj&fc=None&ff=20231218031744&v=2.18.0
-
#Immunogenicity and safety of varying dosages of a fifth-wave #influenza A/ #H7N9 inactivated #vaccine given with and without #AS03 adjuvant in healthy adults https://pubmed.ncbi.nlm.nih.gov/38105137/?utm_source=Feedly&utm_medium=rss&utm_campaign=None&utm_content=1LGAx__djGAJ9poBzWGqPtjEbBDtz4ipSRRPUplmgHEyyF_Ihj&fc=None&ff=20231218031744&v=2.18.0